Patents by Inventor Van T. Tsai

Van T. Tsai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF IL-23 AND IL-17 ANTIAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20140248279
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 4, 2014
    Applicants: Merck Sharp & Dohme Corp., The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20130323251
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: August 6, 2013
    Publication date: December 5, 2013
    Applicants: The Government of the United States of America as represented by the Secretary of the Dep. of H.H.S., Merck Sharp & Dohme Corp.
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
    Patent number: 8524230
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: September 3, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver
  • USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20110142831
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: January 28, 2011
    Publication date: June 16, 2011
    Applicants: Schering Corporation, Department of Health and Human Services
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20100111954
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 6, 2010
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20100111950
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 6, 2010
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
    Publication number: 20080199460
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: August 30, 2006
    Publication date: August 21, 2008
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • Methods and compositions for reducing immune response
    Publication number: 20020187143
    Abstract: The present invention provides an apparatus and method to diminish the pre-existing immune response to the administration of a therapeutic virus by the selective elimination of antiviral antibodies from the serum. The present invention provides a chromatographic material for the elimination of such antibodies. The invention further provides plasmapheresis apparatus comprising this material. The invention further provides methods for the employment of such apparatus as part of therapeutic treatment regiments.
    Type: Application
    Filed: August 16, 2002
    Publication date: December 12, 2002
    Inventors: Drake M. LaFace, Amena Rahman, Paul W. Shabram, Van T. Tsai
  • Methods and compositions for reducing immune response
    Patent number: 6464976
    Abstract: The present invention provides an apparatus and method to diminish the pre-existing immune response to the administration of a therapeutic virus by the selective elimination of antiviral antibodies from the serum. The present invention provides a chromatographic material for the elimination of such antibodies. The invention further provides plasmapheresis apparatus comprising this material. The invention further provides methods for the employment of such apparatus as part of therapeutic treatment regiments.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: October 15, 2002
    Assignee: Canji, Inc.
    Inventors: Drake M. LaFace, Amena Rahman, Paul W. Shabram, Van T. Tsai